Literature DB >> 15602117

Imputing response rates from means and standard deviations in meta-analyses.

Toshi A Furukawa1, Andrea Cipriani, Corrado Barbui, Paolo Brambilla, Norio Watanabe.   

Abstract

The principle of intention-to-treat analysis must be strictly applied to both individual randomized controlled trial and meta-analysis but, in doing so, would involve imputation of some missing data. There is little literature on how to perform this in the case of meta-analysis. For dichotomous outcome measures, one possible strategy is to carry out a sensitivity analysis based on the so-called best case/worst case analyses. For continuous outcomes, it may be possible to achieve this if we can dichotomise the continuous outcomes. Here, we empirically examined the appropriateness of converting continuous outcomes (expressed as mean+/-SD) into dichotomous outcomes (expressed as response rates) in four completed meta-analyses of depression and anxiety, assuming normal distribution of the continuous outcome measures. The agreement between the actually observed versus the imputed raw numbers of responders was indicated by an intraclass correlation coefficient of 0.97 (95% confidence interval 0.95-0.98). The pooled relative risks of the four meta-analyses based on the imputed values were virtually identical to those based on the actually observed values. When individual trials report the means+/-SDs of their outcome measures but fail to report response rates, it may therefore be possible to impute the response rates based on the means+/-SDs, and then submit the meta-analysis to worst case/best case analyses. This would allow a more robust and clinically interpretable estimation of the true, underlying treatment effect to be made.

Entities:  

Mesh:

Year:  2005        PMID: 15602117     DOI: 10.1097/00004850-200501000-00010

Source DB:  PubMed          Journal:  Int Clin Psychopharmacol        ISSN: 0268-1315            Impact factor:   1.659


  90 in total

Review 1.  Mirtazapine versus other antidepressive agents for depression.

Authors:  Norio Watanabe; Ichiro M Omori; Atsuo Nakagawa; Andrea Cipriani; Corrado Barbui; Rachel Churchill; Toshi A Furukawa
Journal:  Cochrane Database Syst Rev       Date:  2011-12-07

Review 2.  [Placebo responders in randomized controlled drug trials of fibromyalgia syndrome : Systematic review and meta-analysis].

Authors:  W Häuser; E Bartram-Wunn; C Bartram; T R Tölle
Journal:  Schmerz       Date:  2011-12       Impact factor: 1.107

3.  Repetitive transcranial magnetic stimulation (rTMS) augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant obsessive-compulsive disorder (OCD): a meta-analysis of randomized controlled trials.

Authors:  Zhong-Rui Ma; Li-Jun Shi
Journal:  Int J Clin Exp Med       Date:  2014-12-15

Review 4.  Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia.

Authors:  T A Furukawa; N Watanabe; R Churchill
Journal:  Cochrane Database Syst Rev       Date:  2007-01-24

Review 5.  Psychological therapies for generalised anxiety disorder.

Authors:  V Hunot; R Churchill; M Silva de Lima; V Teixeira
Journal:  Cochrane Database Syst Rev       Date:  2007-01-24

Review 6.  Effectiveness of psychotherapeutic, pharmacological, and combined treatments for chronic depression: a systematic review (METACHRON).

Authors:  Levente Kriston; Alessa von Wolff; Lars Hölzel
Journal:  BMC Psychiatry       Date:  2010-11-23       Impact factor: 3.630

7.  Placebo response rates and potential modifiers in double-blind randomized controlled trials of second and newer generation antidepressants for major depressive disorder in children and adolescents: a systematic review and meta-regression analysis.

Authors:  Ramona Meister; Mariam Abbas; Jochen Antel; Triinu Peters; Yiqi Pan; Ulrike Bingel; Yvonne Nestoriuc; Johannes Hebebrand
Journal:  Eur Child Adolesc Psychiatry       Date:  2018-12-08       Impact factor: 4.785

Review 8.  Selective serotonin reuptake inhibitors for fibromyalgia syndrome.

Authors:  Brian Walitt; Gerard Urrútia; María Betina Nishishinya; Sarah E Cantrell; Winfried Häuser
Journal:  Cochrane Database Syst Rev       Date:  2015-06-05

9.  Paroxetine versus other anti-depressive agents for depression.

Authors:  Andrea Cipriani; Toshi A Furukawa; Antonio Veronese; Norio Watanabe; Rachel Churchill; Hugh McGuire; Corrado Barbui
Journal:  Cochrane Database Syst Rev       Date:  2007

10.  Venlafaxine versus other anti-depressive agents for depression.

Authors:  Andrea Cipriani; Alessandra Signoretti; Toshi A Furukawa; Rachel Churchill; Silva Tomelleri; Ichiro M Omori; Hugh McGuire; Corrado Barbui
Journal:  Cochrane Database Syst Rev       Date:  2007
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.